Investigating the potential neuroprotective effects of statins on DNA damage in mouse striatum

Food and Chemical Toxicology

Volumn 46, Issue 9, 2008, Pages 3186-3192

  Coetsee, T N ^a   Pretorius, P J ^a   Terre'Blanche, G ^a   Bergh, J J ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Comet assay; DNA damage; DNA repair; MPTP; Oxidative damage; Parkinson's disease; Statins

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ATORVASTATIN; HYDROGEN PEROXIDE; NEUROTOXIN; PRAVASTATIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMET ASSAY; CONTROLLED STUDY; CORPUS STRIATUM; DNA DAMAGE; DNA REPAIR; LIPID OXIDATION; MALE; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN;

ANIMALS; COMET ASSAY; DNA DAMAGE; DNA REPAIR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

MUS;

EID: 50249094320     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2008.07.006     Document Type: Article

References (42)

1. Albano C.B., Muralikrishnan D., and Ebadi M. Distribution of coenzyme Q homologues in brain. Neurochem. Res. 27 (2002) 359-368
2. Aviram M., Rosenblat M., Bisgaier C.L., and Newton R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 (1998) 271-280
3. Bliznakov E.G., and Wilkins D.J. Biochemical and clinical consequences of CoQ10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): A critical review. Adv. Therap. 15 (1998) 218-228
4. +. Exp. Neurol. 18 (2003) 25-38
5. Cassarino D.S., Fall C.P., Swerdlow R.H., Smith T.S., Halvorsen E.M., Miller S.W., Parks J.P., Parker Jr. W.D., and Bennett Jr. J.P. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362 (1997) 77-86
6. Chase T.N., Oh J.D., and Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology 51 (1998) S30-S35
7. Christians U., Jacobsen W., and Floren L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in transplant patients: are the statins mechanistically similar?. Pharmacol. Therapeut. 80 (1998) 1-34
8. Collins A.R. The Comet Assay for DNA damage and repair: principles, applications, and limitations. Mol. Biotechnol. 26 (2004) 249-261
9. Cooke M.S., Olinski R., and Evans M.D. Does measurement of oxidative damage to DNA have clinical significance?. Clin. Chim. Acta 365 (2006) 30-49
10. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
11. Cucchiara B., and Kasner S.E. Use of statins in CNS disorders. J. Neurol. Sci. 187 (2001) 81-89
12. Damrot J., Nübel T., Epe B., Roos W.P., Kaina B., and Fritz G. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Brit. J. Pharmacol. 149 (2006) 988-997
13. Danielson S.R., and Andersen J.K. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radical Bio. Med. 44 (2008) 1787-1794
14. Drechsel D.A., and Patel M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radical Bio. Med. 44 (2008) 1873-1886
15. Dugan L.L., and Choi D.W. Hypoxic-ischemic brain injury and oxidative stress. In: Siegel G.J. (Ed). Basic neurochemistry: molecular, cellular and medical aspects. sixth ed. (1999), Lippincott-Raven, Philadelphia 711-729
16. Ertürk S., Aktaş E.S., Ersoy L., and Fiçicioǧlu S. An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets. J. Pharmaceut. Biomed. 33 (2003) 1017-1023
17. +-induced apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci Res. 55 5 (1999) 620-628
18. Franzoni F., Quiñones-Galvan A., Regoli F., Ferranninia E., and Galettaa F. A comparative study of the in vitro antioxidant activity of statins. Int. J. Cardiol. 90 (2003) 317-321
19. Graham D.G. Oxidative pathway for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14 (1978) 633-643
20. Graham D.G., Tiffany S.M., Bell W.R., and Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14 (1978) 644-653
21. Hamelin B.A., and Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19 (1998) 26-37
22. Hu S., Sheng W.S., Peterson P.K., and Chao C.C. Differential regulation by cytokines of human astrocyte nitric oxide production. Glia 15 (1995) 491-494
23. Human J.A., Ubbink J.B., Jerling J.J., Delport R., Vermaak W.J., Vorster H.H., Lagendijk J., and Potgieter H.C. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin. Chim. Acta 263 (1997) 67-77
24. 2A antagonists as novel non-dopaminergic therapy for motor dysfunction in Parkinson's disease. Neurology 61 (2003) S32-S38
25. Kienzl E., Linert W., Jelllinger K., Puchinger L., Stachelberger H., and Jameson R.F. The role of transition metals in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 134 (1995) 69-78
26. Langston J.W. Predicting Parkinson's disease. Neurology 40 (1990) 70-74
27. Lütjohann D., Stroick M., Bertsch T., Kühl S., Lindenthal B., Thelen K., Andersson U., Björkhem I., Von Bergmann K., and Fassbender K. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69 (2004) 431-438
28. Marnett L.J. Oxyradicals and DNA damage. Carcinogenesis 21 (2000) 361-370
29. Nagatsu T., Mogi M., Ichinose H., and Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm.-Supp. 60 (2000) 277-290
30. Pahan K., Sheikh F.G., Namboodiri A.M., and Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100 (1997) 2671-2679
31. Riess O., and Kruger R. Parkinson's disease: a multifactorial neurodegenerative disorder. J. Neural Transm. 56 (1999) 113-125
32. Sagara Y., Dargusch R., Chambers D., Davis J., Schubert D., and Maher P. Cellular mechanisms of resistance to chronic oxidative stress. Free Radical Bio. Med. 24 (1997) 1375-1389
33. Schmidt N., and Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 108 (2001) 1263-1282
34. Shin M.-J., Cho E.-Y., Jang Y., Lee J.H., Shim W.-H., Cho S.-Y., Rim S.-J., Kang S.-K., Ha J.-W., Ko Y.-H., Kim S.-S., Park H.Y., and Chung N. A beneficial effect of simvastatin on DNA damage in 242T allele of NADPH oxidase p22phox in hypercholesterolemic patients. Clin. Chim. Acta 360 (2005) 46-51
35. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36 (1994) 348-355
36. Singh N.P. Microgels for estimation of DNA strand breaks, DNA protein crosslinks and apoptosis. Mutat. Res-Fund. Mol. M. 455 (2000) 111-127
37. Speciale G.S. MPTP: insights into neurodegeneration. Neurotoxicol. Teratol. 24 (2002) 607-620
38. Vaughan C.J., and Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30 (1999) 1969-1973
39. Vodovotz Y., Lucia M.S., Flanders K.C., Chesler L., Xie Q.W., Smith T.W., Weidner J., Mumford R., Webber R., Nathan C., Roberts A.B., Lippa C.F., and Sporn M.B. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. 184 (1996) 1425-1433
40. Von Bohlen und Halbach O., Schober A., and Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog. Neurobiol. 73 (2004) 151-177
41. Wolozin B., Kellman W., Rousseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol-Chicago 57 (2000) 1439-1443
42. Yoshikawa T. Free radicals and their scavengers in Parkinson's disease. Eur. Neurol. 33 (1993) 60-68